Press Resease

Biologics Outsourcing Market - Global Industry Analysis

Biologics Outsourcing Market by Product (Antibody, Recombinant Protein, Vaccines, and Others), by Type (Kits & Reagents and Instruments), by Sources (Microbial, Mammalian and Others) and for Applications (Vaccine & Therapeutics Development, Blood & Blood Related Products Testing, Cellular and Gene Therapy, Tissue and Tissue Related Products Testing, and Stem Cell Research): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

Published Date: 05-Feb-2018 Category: Pharmaceutical Report Format : PDF Pages: 130 Report Code: ZMR-2577 Status : Published

Global biologics outsourcing market is expected to reach approximately USD 32,000.0 million by 2024 and is expected to exhibit a CAGR of more than 18.0% between 2017 and 2024.

Description

Report Brief

  • The report covers forecast and analysis for the biologics outsourcing market on a global and regional level
  • The report includes the positive and the negative factors that are influencing the growth of the market
  • Detailed information about the market opportunities are discussed
  • The key target audience for the market has been determined in the report
  • The revenue generated by the prominent industry players has been analyzed in the report
  • The market numbers have been calculated using top-down and the bottom-up approaches 
  • The biologics outsourcing market has been analyzed using Porter’s Five Forces Analysis
  • The market is segmented on the basis of product, sources, type, and applications, which in turn bifurcated on regional level as well
  • All the segments have been evaluated based on the present and the future trends
  • The report deals with the in-depth quantitative and qualitative analyses of the Biologics Outsourcing market
  • The report includes the detailed company profiles of the prominent market players

Market Summary

Overview

In global biologics outsourcing market, the biologics are expected to be a significant area of growth, however, they are starting from a lower base and there is a greater bias against outsourcing biologics production. Outsourcing is increasing as a percentage of the whole manufacturing capacity due to relatively more of new product manufacturing is outsourced and facilities with products that become generic are non-core and are being divested. Increasing investments in the research & development of biologics are significantly propelling the outsourcing market among the big as well as small pharmaceutical and biotechnological industries.

Value

The global biologics outsourcing market was valued at around USD 8,420.0 million in the year 2016 and it is expected to reach approximately USD 32,000.0 million by 2024. The global biologics outsourcing market is expected to grow at a CAGR of over 18.0% between 2017 and 2024.

Drivers and Restraints

The major factor driving the growth of biologics outsourcing market is the increasing investments in research & development of biologic drugs. Because of the facilities with products that become generic are non-core and are being divested and relatively more of new product manufacturing is outsourced the outsourcing is increasing as a percentage of the whole manufacturing capacity. Using a third-party manufacturer can act as an additional site in a multiple site supply strategy, provide backup capacity and increased supply security. In addition, biologics capacity has been built up by CMOs to enable more production to be externalized which will ultimately propel the biologics outsourcing market.

Development of Biologics required high capital and time investment which is expected to arrest the growth of this industry in the years to come.

Global Biologics Outsourcing Market

Segmentation

Antibody product segment is accounted for the largest market share in 2017 and expected to dominate the market by the end of forecast period. The antibody segment is further sub-segmented into a monoclonal antibody, bi-specific antibody, and antibody drug conjugates. From which monoclonal antibodies accounted for the largest market share. Increasing approval for an orphan indication has climbed to more than 50% in the current decade will propel the segment during the forecast period.

Microbial source segment dominates the mammalian and other sources such as Transgenic Models, Avian, and etc. number of products discovered and manufactured by microbial sources will keep the segment dominance throughout the forecast period.
The kits & reagents sector is dominating the biologics outsourcing market. Owing to the increasing use of different kits & reagents in numerous clinical trials and other microbiological activities. 

Considering the applications of global biologics market, vaccine & therapeutics development segment is anticipated to hold the largest market share. The factors such as increasing awareness about disease prevention by vaccination and rising investments in R&D of vaccine segment will boost the segment in near future

North America is the largest market for pharmaceutical/biopharmaceutical research, conducting more than three-quarters of the world’s research and development and holding the IP rights for most of the world’s new drug products, hence it the dominating the biologics outsourcing market globally. The Asia Pacific is anticipated to be the most lucrative region in the global biologics outsourcing market. Owing to the increasing pharmaceutical sector in the region and rising government initiatives for the healthcare industry. 

Industry Players

The report includes detailed profiles of the prominent market players that are trending in the market. The list of the players that are compiled in the report is Boehringer Ingelheim GmbH, Catalent, Inc., GenScript, Innovent Biologics, Inc., Syngene, Shanghai Medicilon inc., GL Biochem Corporation Ltd., GVK Biosciences Private Limited, Horizon Discovery Group plc. Innovent Biologics, Inc., Selexis SA, Lonza, Abzena Plc, Adimab LLC., and much more.

The prominent market players maintain the competitive edge in the global market by making investments in the mergers and acquisitions and by increasing their product portfolio. In October 2017, Boehringer Ingelheim and Siamab Therapeutics, Inc. announced that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor-associated carbohydrate antigens (TACAs). 

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global biologics outsourcing market, 2016 – 2024 (USD Million)
    • 2.2. Global biologics outsourcing market: Snapshot
  •  
  • Chapter 3. Biologics outsourcing– Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global biologics outsourcing market drivers: Impact analysis
      • 3.2.2. Increasing R&D spending on biologics drugs
      • 3.2.3. Enormous cost & time-saving advantages
    • 3.3. Market Restraints
      • 3.3.1. Global biologics outsourcing market restraints: Impact analysis
      • 3.3.2. High technical requirement
    • 3.4. Opportunities
      • 3.4.1. Leverage outside technology
    • 3.5. Porter’s five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat of new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by product segment
      • 3.6.2. Market attractiveness analysis, by type segment
      • 3.6.3. Market attractiveness analysis, by source segment
      • 3.6.4. Market attractiveness analysis, by application segment
      • 3.6.5. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global Biologics outsourcing Market – Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global biologics outsourcing market: company market share, 2016
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Therapy Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Therapy and Regional Expansion
    • 4.3. Price Trend Analysis
    • 4.4. Technology Portfolio
  •  
  • Chapter 5. Global Biologics outsourcing Market – Product Segment Analysis
    • 5.1. Global biologics outsourcing market: Product type overview
      • 5.1.1. Global biologics outsourcing market revenue share, by Product, 2016 and 2024
    • 5.2. Antibody
      • 5.2.1. Global Antibody market, 2016 – 2024(USD Million)
      • 5.2.2. Global Antibody market by monoclonal antibody, 2016 – 2024(USD Million)
      • 5.2.3. Global Antibody market by Bi-specific Antibody, 2016 – 2024(USD Million)
      • 5.2.4. Global Antibody market by Antibody Drug Conjugates, 2016 – 2024(USD Million)
    • 5.3. Recombinant Protein
      • 5.3.1. Global Recombinant Protein market , 2016 – 2024(USD Million)
    • 5.4. Vaccines
      • 5.4.1. Global Vaccines market , 2016 – 2024(USD Million)
    • 5.5. Others
      • 5.5.1. Global Others market , 2016 – 2024(USD Million)
  •  
  • Chapter 6. Global Biologics outsourcing Market – Type Segment Analysis
    • 6.1. Global biologics outsourcing market: Type overview
      • 6.1.1. Global biologics outsourcing market revenue share, by Type, 2016 and 2024
    • 6.2. Kits & Reagents
      • 6.2.1. Global Kits & Reagents market , 2016 – 2024(USD Million)
    • 6.3. Instruments
      • 6.3.1. Global Instruments market , 2016 – 2024(USD Million)
  •  
  • Chapter 7. Global Biologics outsourcing Market – Source Segment Analysis
    • 7.1. Global biologics outsourcing market: Source overview
      • 7.1.1. Global biologics outsourcing market revenue share, by Source, 2016 and 2024
    • 7.2. Microbial
      • 7.2.1. Global Microbial source market , 2016 – 2024(USD Million)
    • 7.3. Mammalian
      • 7.3.1. Global Mammalian source market , 2016 – 2024(USD Million)
  •  
  • Chapter 8. Global Biologics outsourcing Market – Application Segment Analysis
    • 8.1. Global biologics outsourcing market: Application overview
      • 8.1.1. Global biologics outsourcing market revenue share, by application, 2016 – 2024
    • 8.2. Vaccine & Therapeutics Development
      • 8.2.1. Global biologics outsourcing market for Vaccine & Therapeutics Development, 2016 – 2024 (USD Million)
    • 8.3. Blood & Blood Related Products Testing
      • 8.3.1. Global biologics outsourcing market for Blood & Blood Related Products Testing, 2016 – 2024(USD Million)
    • 8.4. Cellular and Gene Therapy
      • 8.4.1. Global biologics outsourcing market for Cellular and Gene Therapy, 2016 – 2024 (USD Million)
    • 8.5. Tissue and Tissue Related Products Testing
      • 8.5.1. Global biologics outsourcing market for Tissue and Tissue Related Products Testing, 2016 – 2024 (USD Million)
    • 8.6. Stem Cell Research
      • 8.6.1. Global biologics outsourcing market for Stem Cell Research, 2016 – 2024 (USD Million)
  •  
  • Chapter 9. Global Biologics outsourcing Market – Regional Segment Analysis
    • 9.1. Global biologics outsourcing market: Regional overview
      • 9.1.1. Global biologics outsourcing market revenue share, by region, 2016 and 2024
    • 9.2. North America
      • 9.2.1. North America biologics outsourcing market revenue, by Product, 2014 – 2024 (USD Million)
      • 9.2.2. North America biologics outsourcing market revenue, by Type, 2014 – 2024 (USD Million)
      • 9.2.3. North America biologics outsourcing market revenue, by Source, 2014 – 2024 (USD Million)
      • 9.2.4. North America biologics outsourcing market revenue, by application, 2014 – 2024 (USD Million)
      • 9.2.5. U.S.
      • 9.2.6. Rest of North America
    • 9.3. Europe
      • 9.3.1. Europe biologics outsourcing market revenue, by Product, 2014 – 2024(USD Million)
      • 9.3.2. Europe biologics outsourcing market revenue, by Type, 2014 – 2024(USD Million)
      • 9.3.3. Europe biologics outsourcing market revenue, by Source, 2014 – 2024(USD Million)
      • 9.3.4. Europe biologics outsourcing market revenue, by application, 2014 – 2024(USD Million)
      • 9.3.5. Germany
      • 9.3.6. UK
      • 9.3.7. France
      • 9.3.8. Italy
      • 9.3.9. Spain
      • 9.3.10. Russia
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific biologics outsourcing market revenue, by Product, 2014 – 2024, (USD Million)
      • 9.4.2. Asia Pacific biologics outsourcing market revenue, by Type, 2014 – 2024, (USD Million)
      • 9.4.3. Asia Pacific biologics outsourcing market revenue, by Source, 2014 – 2024, (USD Million)
      • 9.4.4. Asia Pacific biologics outsourcing market revenue, by application, 2014 – 2024, (USD Million)
      • 9.4.5. China
      • 9.4.6. Japan
      • 9.4.7. India
      • 9.4.8. South East Asia
      • 9.4.9. Rest of Asia Pacific
    • 9.5. Latin America
      • 9.5.1. Latin America biologics outsourcing market revenue, by Product, 2014 – 2024(USD Million)
      • 9.5.2. Latin America biologics outsourcing market revenue, by Type, 2014 – 2024(USD Million)
      • 9.5.3. Latin America biologics outsourcing market revenue, by Source, 2014 – 2024(USD Million)
      • 9.5.4. Latin America biologics outsourcing market revenue, by application, 2014 – 2024(USD Million)
      • 9.5.5. Brazil
      • 9.5.6. Rest of Latin America
    • 9.6. Middle East and Africa
      • 9.6.1. Middle East and Africa biologics outsourcing market revenue, by Product, 2014 – 2024 (USD Million)
      • 9.6.2. Middle East and Africa biologics outsourcing market revenue, by Type, 2014 – 2024 (USD Million)
      • 9.6.3. Middle East and Africa biologics outsourcing market revenue, by Source, 2014 – 2024 (USD Million)
      • 9.6.4. Middle East and Africa biologics outsourcing market revenue, by application, 2014 – 2024 (USD Million)
  •  
  • Chapter 10. Company Profile
    • 10.1. BoehringerIngelheim GmbH
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Therapy portfolio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. Catalent, Inc.
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Therapy portfolio
      • 10.2.4. Business strategy
      • 10.2.5. Recent developments
    • 10.3. GenScript
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Therapy portfolio
      • 10.3.4. Business strategy
      • 10.3.5. Recent developments
    • 10.4. Innovent Biologics, Inc.
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Therapy portfolio
      • 10.4.4. Business strategy
      • 10.4.5. Recent developments
    • 10.5. Syngene
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Therapy portfolio
      • 10.5.4. Business strategy
      • 10.5.5. Recent developments
    • 10.6. Shanghai MedicilonInc.
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Therapy portfolio
      • 10.6.4. Business strategy
      • 10.6.5. Recent developments
    • 10.7. GL Biochem Corporation Ltd.
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Therapy portfolio
      • 10.7.4. Business strategy
      • 10.7.5. Recent developments
    • 10.8. GVK Biosciences Private Limited
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Therapy portfolio
      • 10.8.4. Business strategy
      • 10.8.5. Recent developments
    • 10.9. Horizon Discovery Group plc.
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Therapy portfolio
      • 10.9.4. Business strategy
      • 10.9.5. Recent developments
    • 10.10. Albany Molecular Research Inc.
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Therapy portfolio
      • 10.10.4. Business strategy
      • 10.10.5. Recent developments
    • 10.11. Selexis SA
      • 10.11.1. Overview
      • 10.11.2. Financials
      • 10.11.3. Therapy portfolio
      • 10.11.4. Business strategy
      • 10.11.5. Recent developments
    • 10.12. Lonza
      • 10.12.1. Overview
      • 10.12.2. Financials
      • 10.12.3. Therapy portfolio
      • 10.12.4. Business strategy
      • 10.12.5. Recent developments
    • 10.13. Abzena PLC
      • 10.13.1. Overview
      • 10.13.2. Financials
      • 10.13.3. Therapy portfolio
      • 10.13.4. Business strategy
      • 10.13.5. Recent developments
    • 10.14. Adimab LLC.
      • 10.14.1. Overview
      • 10.14.2. Financials
      • 10.14.3. Therapy portfolio
      • 10.14.4. Business strategy
      • 10.14.5. Recent developments
    • 10.15. JHL BIOTECH, INC.
      • 10.15.1. Overview
      • 10.15.2. Financials
      • 10.15.3. Therapy portfolio
      • 10.15.4. Business strategy
      • 10.15.5. Recent developments
    • 10.16. ProteoGenix
      • 10.16.1. Overview
      • 10.16.2. Financials
      • 10.16.3. Therapy portfolio
      • 10.16.4. Business strategy
      • 10.16.5. Recent developments
    • 10.17. Sino Biological Inc.
      • 10.17.1. Overview
      • 10.17.2. Financials
      • 10.17.3. Therapy portfolio
      • 10.17.4. Business strategy
      • 10.17.5. Recent developments
    • 10.18. THE JACKSON LABORATORY
      • 10.18.1. Overview
      • 10.18.2. Financials
      • 10.18.3. Therapy portfolio
      • 10.18.4. Business strategy
      • 10.18.5. Recent developments

List of Figures 

1. Market research process
2. Market research methodology
3. Global biologics outsourcing market revenue, 2016 - 2024(USD Million) 
4. Porter’s five forces analysis
5. Biologics outsourcing Market attractiveness analysis, by Product Segment
6. Biologics outsourcing Market attractiveness analysis, by Type segment
7. Biologics outsourcing Market attractiveness analysis, by Source segment
8. Biologics outsourcing: Market attractiveness analysis, by Application Segment
9. Biologics outsourcing: Market attractiveness analysis, by regional segment
10. Company market share analysis, 2016 
11. Global biologics outsourcing market revenue share by Product, 2016 and 2024
12. Global Antibody market, 2014 – 2024 (USD Million)
13. Global Recombinant Protein market, 2014 – 2024(USD Million)
14. Global Vaccine market, 2014 – 2024(USD Million)
15. Global Others market, 2014 – 2024(USD Million)
16. Global biologics outsourcing market revenue share by Type, 2014 and 2024
17. Global biologics outsourcing market for Kits & Reagents, 2014 – 2024, (USD Million) 
18. Global biologics outsourcing market for instruments, 2014 – 2024, (USD Million) 
19. Global biologics outsourcing market revenue share by Source, 2014 and 2024
20. Global biologics outsourcing market by microbial sources, 2014 – 2024, (USD Million) 
21. Global biologics outsourcing market by mammalian sources, 2014 – 2024, (USD Million) 
22. Global biologics outsourcing market by others sources, 2014 – 2024, (USD Million) 
23. Global biologics outsourcing market revenue share for application, 2014 and 2024
24. Global biologics outsourcing market for Vaccine & Therapeutics Development, 2014 – 2024, (USD Million) 
25. Global biologics outsourcing market for Blood & Blood-Related Products Testing, 2014 – 2024, (USD Million)
26. Global biologics outsourcing market for Cellular and Gene Therapy, 2014 – 2024, (USD Million) 
27. Global biologics outsourcing market for Tissue and Tissue Related Products Testing, 2014 – 2024, (USD Million)
28. Global biologics outsourcing market for Stem Cell Research, 2014 – 2024, (USD Million) 
29. North America Biologics outsourcing Market, By Product, 2017 and 2024
30. North America Biologics outsourcing Market, By Type, 2017 and 2024
31. North America Biologics outsourcing Market, By Sources, 2017 and 2024
32. North America Biologics outsourcing Market, By Application, 2017 and 2024
33. North America Biologics outsourcing Market, By Country, 2017 and 2024
34. Europe Biologics outsourcing Market, By Product, 2017 and 2024
35. Europe Biologics outsourcing Market, By Type, 2017 and 2024
36. Europe Biologics outsourcing Market, By Sources, 2017 and 2024
37. Europe Biologics outsourcing Market, By Application, 2017 and 2024
38. Europe Biologics outsourcing Market, By Country, 2017 and 2024
39. Asia Pacific Biologics outsourcing Market, By Product, 2017 and 2024
40. Asia Pacific Biologics outsourcing Market, By Type, 2017 and 2024
41. Asia Pacific Biologics outsourcing Market, By Sources, 2017 and 2024
42. Asia Pacific Biologics outsourcing Market, By Application, 2017 and 2024
43. Asia Pacific Biologics outsourcing Market, By Country, 2017 and 2024
44. Latin America Biologics outsourcing Market, By Product, 2017 and 2024
45. Latin America Biologics outsourcing Market, By Type, 2017 and 2024
46. Latin America Biologics outsourcing Market, By Sources, 2017 and 2024
47. Latin America Biologics outsourcing Market, By Application, 2017 and 2024
48. Latin America Biologics outsourcing Market, By Country, 2017 and 2024
49. The Middle East & Africa Biologics outsourcing Market, By Product, 2017 and 2024
50. Middle East & Africa Biologics outsourcing Market, By Type, 2017 and 2024
51. Middle East & Africa Biologics outsourcing Market, By Sources, 2017 and 2024
52. Middle East & Africa Biologics outsourcing Market, By Application, 2017 and 2024
53. The Middle East & Africa Biologics outsourcing Market, By Country, 2017 and 2024


List of Tables

1. Biologics outsourcing market: Market Snapshot                                                                          
2. Drivers of global Biologics outsourcing market: Impact analysis 
3. Restraints of global Biologics outsourcing market: Impact analysis  
4. North America Biologics outsourcing market revenue, by product, 2014 – 2024 (USD Million) 
5. North America Biologics outsourcing market revenue, by type, 2014 – 2024 (USD Million) 
6. North America Biologics outsourcing market revenue, by source, 2014 – 2024 (USD Million) 
7. North America Biologics outsourcing market revenue, by application, 2014 – 2024 (USD Million) 
8. North America Biologics outsourcing market revenue, by Country, 2014 – 2024 (USD Million) 
9. Europe Biologics outsourcing market revenue, by product, 2014 – 2024 (USD Million) 
10. Europe Biologics outsourcing market revenue, by type, 2014 – 2024 (USD Million) 
11. Europe Biologics outsourcing market revenue, by source, 2014 – 2024 (USD Million) 
12. Europe Biologics outsourcing market revenue, by application, 2014 – 2024 (USD Million) 
13. Europe Biologics outsourcing market revenue, by Country, 2014 – 2024 (USD Million)
14. Asia Pacific Biologics outsourcing market revenue, by product, 2014 – 2024 (USD Million) 
15. Asia Pacific Biologics outsourcing market revenue, by type, 2014 – 2024 (USD Million) 
16. Asia Pacific Biologics outsourcing market revenue, by source, 2014 – 2024 (USD Million) 
17. Asia Pacific Biologics outsourcing market revenue, by application, 2014 – 2024 (USD Million) 
18. Asia Pacific Biologics outsourcing market revenue, by country, 2014 – 2024 (USD Million)
19. Latin America Biologics outsourcing market revenue, by product, 2014 – 2024 (USD Million) 
20. Latin America Biologics outsourcing market revenue, by type, 2014 – 2024 (USD Million) 
21. Latin America Biologics outsourcing market revenue, by source, 2014 – 2024 (USD Million) 
22. Latin America Biologics outsourcing market revenue, by application, 2014 – 2024 (USD Million) 
23. Latin America Biologics outsourcing market revenue, by Country, 2014 – 2024 (USD Million)
24. Middle East and Africa Biologics outsourcing market revenue, by product, 2014 – 2024 (USD Million)
25. Middle East and Africa Biologics outsourcing market revenue, by type, 2014 – 2024 (USD Million)
26. Middle East and Africa Biologics outsourcing market revenue, by source, 2014 – 2024 (USD Million)
27. Middle East and Africa Biologics outsourcing market revenue, by application, 2014 – 2024 (USD Million)
28. Middle East and Africa Biologics outsourcing market revenue, by Country, 2014 – 2024 (USD Million)
 

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Biologics Outsourcing market. Zion Market Research has collected and analyzed key data belong to the global Biologics Outsourcing market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account, while estimating market size. The revenue generated by the leading industry participants in from the sales of Biologics Outsourcingacross the world has been calculated through primary and secondary research.

Zion Market Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Biologics Outsourcing industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Biologics Outsourcing market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed